Back to "A 4-P MACE event occurred in 127 patient..."
Strong Support
causal
Analysis v3
History

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the chance of having a heart attack, stroke, or needing a procedure to restore blood flow over...

80
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

This drug helps the liver remove more bad cholesterol from the blood by keeping more cleanup receptors active. With less cholesterol in the blood, it doesn't build up in artery walls, which stops new blockages from forming and prevents the need for procedures to open arteries or have heart attacks...

Most probable mechanism

In Simple Terms

A drug blocks a protein that normally removes cholesterol-clearing receptors from the liver, so more receptors stay on the liver surface to pull bad cholesterol out of the blood. With less cholesterol in the blood, it doesn't build up in artery walls as much, which keeps new blockages from forming and stops existing tiny blockages from turning into heart attacks, strokes, or needing surgery to open arteries.

Causal chain
1

A monoclonal antibody binds to and neutralizes PCSK9 protein in the bloodstream

Verified by multiple studies
which leads to
2

Neutralized PCSK9 cannot bind to LDL receptors on hepatocytes, preventing their degradation

Verified by multiple studies
which leads to
3

LDL receptors are recycled to the hepatocyte membrane instead of being destroyed in lysosomes

Verified by multiple studies
which leads to
4

Increased LDL receptor density on hepatocytes enhances clearance of LDL particles from plasma

Verified by multiple studies
which leads to
5

Sustained reduction in plasma LDL cholesterol decreases lipid deposition into the arterial intima

Verified by multiple studies
which leads to
6

Reduced lipid accumulation slows initiation and progression of atherosclerotic lesions and promotes stabilization of early plaques

Verified by multiple studies
which leads to
7

Stabilized plaques and reduced plaque burden lower the likelihood of rupture, thrombus formation, and subsequent ischemic events such as myocardial infarction, stroke, or revascularization

Verified by multiple studies

Evidence from Studies

Supporting (1)

80

Community contributions welcome

80

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Randomized Controlled Trial
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Score: 80
DOI: 10.1001/jama.2026.3277

Similar Assertions

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab is associated with a reduction in the risk of death from any cause over five years, from 10.1% to 7.8%.

80
0
91%

In adults with diabetes who do not have advanced artery disease, the drug evolocumab lowers the chance of having a heart attack, stroke, or needing a procedure to restore blood flow over five years, compared to a placebo.

80
0
90%

For adults with diabetes who do not have advanced artery disease, taking evolocumab for five years lowers the chance of having a first heart attack, stroke, or other major cardiovascular event by 2.1 percentage points. This means that treating 48 people with this drug would prevent one such event over five years.

80
0
89%

In adults with diabetes who do not have advanced artery disease, a drug called evolocumab lowers LDL cholesterol by about half after 48 weeks of treatment, resulting in significantly lower cholesterol levels compared to a placebo.

80
0
86%

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the risk of dying from any cause over five years compared to a placebo.

80
0
86%